| Mixed-phenotype acute leukemia treated with decitabine |
|
Lee, Ji-Young
(Division of Hematology/Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital)
Lee, Sang-min (Division of Hematology/Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital) Lee, Ja-Young (Department of Laboratory Medicine, Inje University Busan Paik Hospital) Kim, Ki-Hyang (Division of Hematology/Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital) Choi, Moon-Young (Division of Hematology/Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital) Lee, Won-Sik (Division of Hematology/Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital) |
| 1 | Steensma DP. Oddballs: acute leukemias of mixed phenotype and ambiguous origin. Hematol Oncol Clin North Am 2011;25:1235-1253. DOI |
| 2 | Matutes E, Pickl WF, Van't Veer M, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood 2011;117:3163-3171. DOI |
| 3 | Garcia-Manero G, Thomas DA, Rytting ME, et al. Final report of a phase 1 trial of decitabine with or without hyperCVAD in relapsed acute lymphocytic leukemia. Blood 2010;116:867. |
| 4 | Burke MJ, Lamba JK, Pounds S, et al. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol 2014;89:889-895. DOI |
| 5 | Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012;30:2670-2677. DOI |
 |
Korea Institute of Science and Technology Information
Gwahangno, Yuseong-gu, Daejeon, 305-806, Korea TEL : +82-42-869-1752
Copyright (c) 2009 KISTI. All Rights Reserved. For more information mail to
webmaster
